Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis
Kwonjune J. Seung, Palwasha Khan, Molly F. Franke, Saman Ahmed, Stalbek Aiylchiev, Manzur Alam, Fauziah Asnely Putri, Mathieu Bastard, et al. (26 authors)
Clinical Infectious Diseases · 2019-10
Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
MeSH terms
- Medicine
- Culture conversion
- Sputum
- Regimen
- Tuberculosis
- Sputum culture
- Observational study
- Multiple drug resistance
- Internal medicine
- Bedaquiline
- Clinical trial
- Intensive care medicine
- Drug resistance
- Mycobacterium tuberculosis